Expanded FDA indications and Medicare coverage of semaglutide for cardiovascular risk prevention were associated with increased Wegovy utilization, most notably through Medicare Part D.
Christopher Scannell, MD, PhD
Advertisement
Articles by Christopher Scannell, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Moderna, Merck mRNA Cancer Vaccine Succeeds in Late-Stage Trial
2
5 Things to Know About the FDA's Peptide Reversal
3
Iberdomide Complements CAR T in Myeloma: Swarup Kimar, MD
4
Escalation of Atopic Dermatitis Care Requires Addressing Barriers
5